for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QIA.DE

Latest Trade

40.23EUR

Change

0.23(+0.58%)

Volume

408,321

Today's Range

39.92

 - 

40.47

52 Week Range

22.54

 - 

42.98

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
40.00
Open
40.03
Volume
408,321
3M AVG Volume
16.72
Today's High
40.47
Today's Low
39.92
52 Week High
42.98
52 Week Low
22.54
Shares Out (MIL)
228.49
Market Cap (MIL)
9,196.28
Forward P/E
27.46
Dividend (Yield %)
--

Next Event

Q3 2020 Qiagen NV Earnings Release

Latest Developments

More

Qiagen Reports Full Results For Second Quarter And First Half Of 2020

Qiagen Publishes Position Statement For Proposed Acquisition By Thermo Fisher

Davidson Kempner Says It Is Increasingly Apparent That Fair Value Of Qiagen Is Well In Excess Of Current Stock Price

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry

Biotechnology & Drugs

Contact Info

Hulsterweg 82

5912 PL

Netherlands

+31.77.3556600

https://www.qiagen.com/

Executive Leadership

Hakan Bjorklund

Independent Chairman of the Supervisory Board

Thierry Bernard

Chief Executive Officer, Senior Vice President - Molecular Diagnostics Business Area, Member of the Executive Committee

Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Committee

Stephane Bancel

Independent Member of the Supervisory Board

Metin Colpan

Independent Member of the Supervisory Board

Key Stats

3.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.4K

2018

1.5K

2019

1.5K

2020(E)

1.8K
EPS (USD)

2017

1.270

2018

1.340

2019

1.430

2020(E)

1.851
Price To Earnings (TTM)
1,099.02
Price To Sales (TTM)
6.78
Price To Book (MRQ)
4.14
Price To Cash Flow (TTM)
49.47
Total Debt To Equity (MRQ)
65.09
LT Debt To Equity (MRQ)
53.42
Return on Investment (TTM)
0.32
Return on Equity (TTM)
0.26

Latest News

Latest News

Davidson Kempner says again it will not be tendering Qiagen shares

Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen <QIA.DE>, days after Thermo Fisher Scientific <TMO.N> said its offer to buy the German genetic test maker expires soon.

Davidson Kempner says again it will not be tendering Qiagen shares

Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen , days after Thermo Fisher Scientific said its offer to buy the German genetic test maker expires soon.

Qiagen investor Davidson Kempner ups stake to 8%

Hedge fund Davidson Kempner said on Monday it had raised its stake in takeover target Qiagen <QIA.DE> to 8% from 7.3% previously, reaffirming its opposition to Thermo Fisher's <TMO.N> 11.3 billion euro (10.1 billion pounds) bid.

Davidson Kempner ups stake in Qiagen to 7.3%

Hedge fund Davidson Kempner has raised its stake in takeover target Qiagen <QIA.DE> to 7.3% from 5.1% previously, having rejected a sweetened offer for the German group from U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.

Qiagen investor PSquared won't tender shares in Thermo Fisher bid

Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen <QIA.DE>, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.

Breakingviews - Corona Capital: Newspapers, 747s

Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

PRESS DIGEST-Financial Times - July 17

The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Thermo Fisher's sweetened Qiagen bid fails to win over key investor

Thermo Fisher Scientific raised its bid for Qiagen by 900 million euros ($1 billion) on Thursday but failed to win over a key investor who is seeking a higher price for the German genetic test maker.

Davidson Kempner spurns Thermo Fisher's Qiagen offer as 'wholly inadequate'

Hedge fund Davidson Kempner said on Wednesday Thermo Fisher Scientific's <TMO.N> offer to buy German genetic test maker Qiagen <QIA.DE> was "wholly inadequate" and that it would not be tendering its shares into the deal at the current price.

Davidson Kempner says won't tender its Qiagen shares at current Thermo Fisher offer price

Hedge fund Davidson Kempner said on Wednesday Thermo Fisher's acquisition offer for German genetic test maker Qiagen was "wholly inadequate" and that it would not tenderings its share into the deal at the current offer.

Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'

Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's <TMO.N> current offer to acquire German genetic test maker Qiagen NV <QIA.DE> to be "inadequate" and would not tender its shares into the offer.

Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'

Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's current offer to acquire German genetic test maker Qiagen NV to be "inadequate" and will not tender its shares into the offer.

Daily Briefing: One step forward, two steps back

U.S. 10-year Treasury yields are at their lowest since mid-May, the safe-haven yen is at a two-week high, Asian shares and U.S. stock futures are down sharply. European stocks have just opened down.

European shares enter fourth day of declines, energy firms drag

European shares extended losses for a fourth straight session on Friday on worries that an economic recovery may fizzle out as coronavirus cases continue to rise globally.

Qiagen reports strong quarter as sales of coronavirus test products rise

The German genetic testing firm Qiagen <QIA.DE> on Thursday reported a preliminary 18-19% rise in sales and a 68% rise in earnings per share in the second quarter amid strong demand for products used in coronavirus testing.

BRIEF-Qiagen Q2 Net Sales Rose About 18-19% Compared To Year Ago

* Q2 NET SALES ROSE APPROXIMATELY 18-19% AT CONSTANT EXCHANGE RATES (CER) FROM $381.6 MILLION IN SAME PERIOD OF 2019

Major Qiagen shareholder demands higher bid from Thermo Fisher - source

The coronavirus pandemic has boosted Qiagen's <QIA.DE> prospects and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.

Major Qiagen shareholder opposes Thermo Fisher takeover - source

The coronavirus pandemic has boosted Qiagen's prospects as a standalone company and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.

German stocks - Factors to watch on June 24

The following are some of the factors that may move German stocks on Wednesday:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up